butyric acid has been researched along with Parkinson Disease in 6 studies
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.
butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.
butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Research has connected Parkinson's disease (PD) with impaired intestinal barrier." | 1.72 | Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice. ( Ding, ST; Jian, YX; Lei, YH; Liu, HD; Liu, MR; Miao, WT; Xu, JY; Xu, RC; Xu, WX; Yan, N, 2022) |
| "Therapeutic options for Parkinson's disease (PD) are limited to a symptomatic approach, making it a global threat." | 1.62 | Neuroprotective Effects of Trehalose and Sodium Butyrate on Preformed Fibrillar Form of α-Synuclein-Induced Rat Model of Parkinson's Disease. ( Dubey, SK; K C, S; Kakoty, V; Taliyan, R; Yang, CH, 2021) |
| "However, the pathogenesis of Parkinson's disease is still incompletely understood to date." | 1.42 | G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson's Disease Patients. ( Alquézar, C; Bartolomé, F; Bermejo-Pareja, F; de la Encarnación, A; Esteras, N; Martín-Requero, Á; Molina, JA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, RC | 1 |
| Miao, WT | 1 |
| Xu, JY | 1 |
| Xu, WX | 1 |
| Liu, MR | 1 |
| Ding, ST | 1 |
| Jian, YX | 1 |
| Lei, YH | 1 |
| Yan, N | 1 |
| Liu, HD | 2 |
| Guo, TT | 1 |
| Zhang, Z | 1 |
| Sun, Y | 1 |
| Zhu, RY | 1 |
| Wang, FX | 1 |
| Ma, LJ | 1 |
| Jiang, L | 1 |
| Kakoty, V | 1 |
| K C, S | 1 |
| Dubey, SK | 1 |
| Yang, CH | 1 |
| Taliyan, R | 1 |
| Paiva, I | 1 |
| Pinho, R | 1 |
| Pavlou, MA | 1 |
| Hennion, M | 1 |
| Wales, P | 1 |
| Schütz, AL | 1 |
| Rajput, A | 1 |
| Szego, ÉM | 1 |
| Kerimoglu, C | 1 |
| Gerhardt, E | 1 |
| Rego, AC | 1 |
| Fischer, A | 1 |
| Bonn, S | 1 |
| Outeiro, TF | 1 |
| Esteras, N | 1 |
| Alquézar, C | 1 |
| Bartolomé, F | 1 |
| de la Encarnación, A | 1 |
| Bermejo-Pareja, F | 1 |
| Molina, JA | 1 |
| Martín-Requero, Á | 1 |
| Jin, H | 1 |
| Kanthasamy, A | 1 |
| Harischandra, DS | 1 |
| Kondru, N | 1 |
| Ghosh, A | 1 |
| Panicker, N | 1 |
| Anantharam, V | 1 |
| Rana, A | 1 |
| Kanthasamy, AG | 1 |
6 other studies available for butyric acid and Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective Effects of Sodium Butyrate and Monomethyl Fumarate Treatment through GPR109A Modulation and Intestinal Barrier Restoration on PD Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Butyric Acid; Claudin-1; Cytokines; Disease M | 2022 |
Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson's Disease.
Topics: Animals; Butyric Acid; Disease Models, Animal; Dysbiosis; Gastrointestinal Microbiome; Inflammation; | 2023 |
Neuroprotective Effects of Trehalose and Sodium Butyrate on Preformed Fibrillar Form of α-Synuclein-Induced Rat Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Butyric Acid; Disease Models, Animal; Neuroprotective Agents; Parkinson Di | 2021 |
Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage.
Topics: alpha-Synuclein; Butyric Acid; Cell Culture Techniques; DNA Damage; Dopaminergic Neurons; Gene Expre | 2017 |
G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson's Disease Patients.
Topics: Aged; Aged, 80 and over; Butyric Acid; Case-Control Studies; Cell Cycle Checkpoints; Cell Cycle Prot | 2015 |
Histone hyperacetylation up-regulates protein kinase Cδ in dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in Parkinson disease.
Topics: Acetylation; Animals; Brain; Butyric Acid; Cell Death; Cell Line; Dopaminergic Neurons; Epigenesis, | 2014 |